BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
nab-paclitaxel: trial readouts and FDA decisions
6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: SynerGene Therapeutics, Inc., Akeso, CStone Pharmaceuticals, Huabo Biopharm Co., Ltd., Gilead Sciences, Astellas Pharma Global Development, Inc., Biotheus Inc., Hoffmann-La Roche, SynerGene Therapeutics, Inc., Huabo Biopharm Co., Ltd., Astellas Pharma Global Development, Inc., Verastem, Inc., Panbela Therapeutics, Inc., DualityBio Inc., Revolution Medicines, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | SynerGene Therapeutics, Inc. | NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | active not recruiting | 28 |
| 2026-12 est. | P3 | Akeso | NCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Triple-Negative Breast Cancer (TNBC) | recruiting | 416 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01-15 est. | P2 | Huabo Biopharm Co., Ltd. | NCT07376629 A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | enrolling by invitation | 60 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2026-12-30 est. | P1/P2 | Akeso | NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 110 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-31 est. | P2 | Astellas Pharma Global Development, Inc. | NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma | active not recruiting | 393 |
| 2026-10-30 est. | P1/P2 | Biotheus Inc. | NCT05918133 A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | active not recruiting | 42 |
| 2026-10-15 | P2 | Hoffmann-La Roche | NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced | Breast Cancer | completed | 83 |
| 2026-08-31 est. | P1/P2 | Verastem, Inc. VSTM | NCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neopla | active not recruiting | 40 |
| 2026-08-29 est. | P2/P3 | Panbela Therapeutics, Inc. | NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV | recruiting | 600 |
| 2026-08-12 | P3 | DualityBio Inc. | NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Metastatic Breast Cancer | active not recruiting | 541 |
| 2026-06 est. | P3 | Revolution Medicines, Inc. RVMD | NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | active not recruiting | 500 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.